In which clinical situations should metformin be avoided or not initiated?

When to Avoid or Not Initiate Metformin

Metformin is absolutely contraindicated when eGFR is below 30 mL/min/1.73 m² and should not be initiated when eGFR is between 30–45 mL/min/1.73 m²; it must also be avoided in patients with hepatic impairment, acute hypoxic states, or conditions predisposing to lactic acidosis. 1, 2, 3

Absolute Contraindications (Do Not Initiate)

Severe Renal Impairment

• eGFR < 30 mL/min/1.73 m²: Metformin is absolutely contraindicated because reduced renal clearance causes drug accumulation and markedly increases the risk of fatal lactic acidosis. 1, 2, 3
• eGFR 30–44 mL/min/1.73 m²: Initiation is not recommended in treatment-naïve patients, though continuation with dose reduction (≤1000 mg daily) may be considered in patients already on therapy. 2, 3
• End-stage renal disease (ESRD) or dialysis: Metformin must be stopped when patients reach ESRD; insulin becomes the only safe glucose-lowering medication across all levels of kidney function. 1

Hepatic Impairment

• Any clinical or laboratory evidence of hepatic disease: Avoid metformin because impaired lactate clearance results in higher lactate blood levels and increased lactic acidosis risk. 3

Acute Hypoxic States

• Acute congestive heart failure (particularly with hypoperfusion/hypoxemia): Discontinue immediately. 3
• Cardiovascular collapse (shock): Absolute contraindication. 3
• Acute myocardial infarction: Stop metformin. 3
• Sepsis or severe infection: Discontinue due to lactic acidosis risk. 3, 4
• Respiratory insufficiency or hypoxemia: Contraindicated. 3, 4

Dehydration and Volume Depletion

• Acute dehydration from vomiting, diarrhea, or prolonged fasting: Hold metformin temporarily. 2, 3
• Surgery requiring restricted food/fluid intake: Temporarily discontinue metformin perioperatively. 2, 3

Alcohol Abuse

• Excessive or chronic alcohol intake: Alcohol potentiates metformin's effect on lactate metabolism; avoid use in patients with alcoholism. 3

Situations Requiring Temporary Discontinuation

Iodinated Contrast Procedures

• Stop metformin at the time of or prior to contrast administration when any of the following apply: 2, 3
  • eGFR 30–60 mL/min/1.73 m²
  • History of hepatic impairment, alcoholism, or heart failure (regardless of eGFR)
  • Intra-arterial contrast administration
• Re-evaluate eGFR 48 hours after the procedure before restarting metformin; resume only if renal function is stable. 2, 3

Acute Illness ("Sick-Day" Rules)

• Temporarily hold metformin during: 2, 3
  • Acute kidney injury or rapid decline in renal function
  • Severe infection or sepsis
  • Acute heart failure or cardiovascular collapse
  • Respiratory insufficiency
  • Dehydration or volume depletion
  • Surgery requiring prolonged fasting

Special Populations Requiring Caution

Elderly Patients (≥65 Years)

• Assess renal function more frequently because elderly patients have greater likelihood of hepatic, renal, or cardiac impairment. 2, 3
• Age-related muscle loss can mask declining eGFR when using serum creatinine alone; always calculate eGFR. 2

Patients ≥80 Years

• Do not initiate metformin unless kidney function has been tested and confirmed to be adequate. 3

Monitoring Requirements Before Initiation

Mandatory Pre-Initiation Assessment

• Obtain eGFR before starting metformin; this is required by FDA labeling. 3
• Assess for hepatic disease through clinical history and laboratory evidence. 3
• Evaluate volume status and correct any depletion before initiation. 2
• Screen for alcohol use and counsel against excessive intake. 3

Common Pitfalls to Avoid

Do Not Rely Solely on Serum Creatinine

• Always calculate eGFR rather than using serum creatinine thresholds alone (the historic FDA black-box warning used creatinine ≥1.5 mg/dL in men, ≥1.4 mg/dL in women, but this is outdated). 2

Do Not Ignore Contraindications Despite Observational Data

• Some observational studies suggest continuing metformin in stage 4 CKD may be associated with lower mortality, but this is low-quality evidence and current guidelines maintain the recommendation to discontinue at eGFR <30 mL/min/1.73 m². 2
• The risk of fatal lactic acidosis outweighs any potential benefit in ESRD. 1

Do Not Forget Sick-Day Education

• Educate all patients to recognize symptoms of lactic acidosis (weakness, unusual muscle pain, trouble breathing, unusual sleepiness, stomach problems, feeling cold, dizziness, slow/irregular heartbeat) and to stop metformin and seek immediate care. 3
• Provide written instructions to hold metformin during acute illness. 2

Alternative Therapies When Metformin Is Contraindicated

eGFR 25–45 mL/min/1.73 m²

• SGLT2 inhibitors (dapagliflozin 10 mg daily) can be initiated for cardiovascular and kidney protection when eGFR ≥25 mL/min/1.73 m², though glucose-lowering efficacy is lost below 45 mL/min/1.73 m². 1, 5
• GLP-1 receptor agonists require no dose adjustment for CKD and provide cardiorenal protection. 2

eGFR <30 mL/min/1.73 m² or ESRD

• Insulin is the only glucose-lowering medication that is both safe and cost-effective across all levels of kidney function, including dialysis. 1
• Linagliptin is the only DPP-4 inhibitor that does not require dose adjustment in ESRD and can be used safely in dialysis patients. 1
• Glipizide (not glyburide) may be used with intensive hypoglycemia counseling, though it carries high hypoglycemia risk. 1